<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8415">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146404</url>
  </required_header>
  <id_info>
    <org_study_id>1H_lac_acc</org_study_id>
    <nct_id>NCT02146404</nct_id>
  </id_info>
  <brief_title>The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow</brief_title>
  <official_title>The Effect of Insulin-induced Hypoglycemia on Brain Lactate Accumulation and Regional Cerebral Blood Flow in Patients With Type 1 Diabetes Mellitus With and Without Hypoglycemia Unawareness and Non-diabetic Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iatrogenic hypoglycemia is the most frequent acute complication of insulin therapy in people
      with type 1 diabetes (T1DM). Recurrent hypoglycemic events initiate a process of
      habituation, characterized by suppression of hypoglycemic symptoms and lead to hypoglycemia
      unawareness, which in itself defines a particularly high risk of severe hypoglycemia. Recent
      evidence suggest a pivotal role for increased brain lactate transport capacity in the
      pathogenesis of hypoglycemia unawareness. However, there is uncertainty about the magnitude
      of this effect and whether such excess brain lactate is oxidizes as a glucose-sparing
      alternative energy source or acts as a metabolic regulator controlling brain glucose
      metabolism, oxygen consumption and cerebral blood flow.

      Objective: The primary objective of this study is to investigate the effect of hypoglycemia
      on brain lactate accumulation and regional cerebral blood perfusion in humans. The secondary
      objective is to assess whether this effect is a related to hypoglycemia unawareness or a
      consequence of T1DM per se.

      Hypothesis: The investigators hypothesize that hypoglycemia stimulates lactate transport
      over the blood-brain barrier leading to cerebral lactate accumulation and that this lactate
      accumulation is a function of prior hypoglycemic exposure frequency contributing to clinical
      hypoglycemia unawareness. Furthermore, the investigators expect that this effect of
      hypoglycemia on brain lactate accumulation is related to changes in cerebral blood flow
      (CBF).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Brain lactate concentration</measure>
    <time_frame>during 30 minutes of hypoglycemia or euglycemia</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration brain lactate measured with 1H-MRS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain lactate concentration</measure>
    <time_frame>during 30 minutes of hypoglycemia or euglycemia</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration brain lactate measured with 1H magnetic resonance spectroscopy (MRS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia Unawareness</condition>
  <arm_group>
    <arm_group_label>Euglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma glucose levels will be clamped at a constant value of ~5.0 mmol/l</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma glucose levels will be clamped at a stable value of ~3.0 mmol/l</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glucose clamp</intervention_name>
    <arm_group_label>Euglycemia</arm_group_label>
    <arm_group_label>Hypoglycemia</arm_group_label>
    <other_name>Stepped hyperinsulinemic euglycemic-hypoglycemic glucose clamp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for healthy subjects

          -  Age: 18-50 years

          -  Body-Mass Index: 18-30 kg/m2

          -  Blood pressure: &lt;160/90 mmHg

        Inclusion criteria T1DM patients with normal hypoglycemic awareness

          -  Diabetes duration ≥ 1 year

          -  Age: 18-50 years

          -  Body-Mass Index: 18-30 kg/m2

          -  HbA1c: 42-75 mmol/mol (6-9%)

          -  Outcome Clarke questionnaire: 0-1

          -  Blood pressure: &lt;160/90 mmHg

        Inclusion criteria T1DM patients with hypoglycemia unawareness

          -  Diabetes duration ≥ 1 year

          -  Age: 18-50 years

          -  Body-Mass Index: 18-30 kg/m2

          -  HbA1c: 42-75 mmol/mol (6-9%)

          -  Outcome Clarke questionnaire: &gt;3

          -  Blood pressure: &lt;160/90 mmHg

        Exclusion criteria for healthy subjects

          -  Inability to provide informed consent

          -  Presence of any medical condition that might interfere with the study protocol, such
             as brain injuries, epilepsy, a major cardiovascular disease event or anxiety
             disorders

          -  Use of any medication, except for oral contraceptives

          -  MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body)

        Exclusion criteria for all T1DM patients

          -  Inability to provide informed consent

          -  Presence of any other medical condition that might interfere with the study protocol,
             such as brain injuries, epilepsy, a major cardiovascular disease event, anxiety
             disorders, or complications of T1DM (including neuropathy and retinopathy)

          -  Use of any other medication than insulin, except for oral contraceptives or stable
             thyroxine supplementation therapy

          -  MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bastiaan de Galan, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud umc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanne Rooijackers, Drs.</last_name>
    <email>Hanne.Rooijackers@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Evita Wiegers, Msc.</last_name>
    <email>evita.wiegers@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud umc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van de Ven KC, van der Graaf M, Tack CJ, Klomp DW, Heerschap A, de Galan BE. Optimized [1-(13)C]glucose infusion protocol for 13C magnetic resonance spectroscopy at 3T of human brain glucose metabolism under euglycemic and hypoglycemic conditions. J Neurosci Methods. 2010 Jan 30;186(1):68-71. doi: 10.1016/j.jneumeth.2009.10.025. Epub 2009 Nov 11.</citation>
    <PMID>19913052</PMID>
  </reference>
  <reference>
    <citation>van de Ven KC, de Galan BE, van der Graaf M, Shestov AA, Henry PG, Tack CJ, Heerschap A. Effect of acute hypoglycemia on human cerebral glucose metabolism measured by ¹³C magnetic resonance spectroscopy. Diabetes. 2011 May;60(5):1467-73. doi: 10.2337/db10-1592. Epub 2011 Apr 4.</citation>
    <PMID>21464446</PMID>
  </reference>
  <reference>
    <citation>van de Ven KC, van der Graaf M, Tack CJ, Heerschap A, de Galan BE. Steady-state brain glucose concentrations during hypoglycemia in healthy humans and patients with type 1 diabetes. Diabetes. 2012 Aug;61(8):1974-7. doi: 10.2337/db11-1778. Epub 2012 Jun 11.</citation>
    <PMID>22688331</PMID>
  </reference>
  <reference>
    <citation>van de Ven KC, Tack CJ, Heerschap A, van der Graaf M, de Galan BE. Patients with type 1 diabetes exhibit altered cerebral metabolism during hypoglycemia. J Clin Invest. 2013 Feb 1;123(2):623-9. doi: 10.1172/JCI62742. Epub 2013 Jan 9.</citation>
    <PMID>23298837</PMID>
  </reference>
  <reference>
    <citation>Herzog RI, Jiang L, Herman P, Zhao C, Sanganahalli BG, Mason GF, Hyder F, Rothman DL, Sherwin RS, Behar KL. Lactate preserves neuronal metabolism and function following antecedent recurrent hypoglycemia. J Clin Invest. 2013 May 1;123(5):1988-98. doi: 10.1172/JCI65105. Epub 2013 Apr 1.</citation>
    <PMID>23543056</PMID>
  </reference>
  <reference>
    <citation>De Feyter HM, Mason GF, Shulman GI, Rothman DL, Petersen KF. Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Diabetes. 2013 Sep;62(9):3075-80. doi: 10.2337/db13-0313. Epub 2013 May 28.</citation>
    <PMID>23715622</PMID>
  </reference>
  <reference>
    <citation>Bergersen LH, Gjedde A. Is lactate a volume transmitter of metabolic states of the brain? Front Neuroenergetics. 2012 Mar 19;4:5. doi: 10.3389/fnene.2012.00005. eCollection 2012.</citation>
    <PMID>22457647</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Hypoglycemia unawareness</keyword>
  <keyword>1H MRS</keyword>
  <keyword>Lactate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Unconsciousness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
